Author(s):
Harshada Kailas Patil, Hetakshi Vilas Patil, Mohit Sunil Pawar, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
Email(s):
patilharshada1782001@gmail.com
DOI:
10.52711/2231-5675.2025.00024 
Address:
Harshada Kailas Patil*, Hetakshi Vilas Patil, Mohit Sunil Pawar, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
P.S.G.V.P Mandal’s College of Pharmacy, Shahada, Dist - Nandurbar, Maharashtra - India. Postal Code: 425409.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Safinamide Mesylate (SAF) (S1), also known as (S)-2-(4-((3-Fluorobenzyl) oxy) benzyl) amino) propanamide methane sulfonate, is a recently developed medicine to treat Parkinson's disease (PD). Safinamide is a third-generation reversible MAO-B inhibitor, which also blocks sodium voltage-sensitive channels and modulates stimulated release of glutamate. Safinamide used to supplement levodopa/carbidopa for Parkinson's disease therapy during "off" episodes. According to the literature, there are many methods for the analysis of Safinamide Mesylate, so we gather all methods in one review. Safinamide was monitored using High Performance liquid Chromatography (HPLC), High Performance Thin Layer Chromatography (HPTLC), and Bio analytical Method Development of Safinamide by UPLC-MS/MS, and RP-HPLC, Stability Indicating assay method for development and validation. The primary focus is on chromatographic methods, particularly High-Performance liquid Chromatography (HPLC), which remains the most preferred approach due to its robustness, accuracy and precision. Several key factors involved in method development, including column type, detection wavelength, and mobile phase compositions are discussed in details. Furthermore, critical validation parameters, such as linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), are examined in accordance with the guidelines set by the international council for harmonization (ICH) and other regulatory authorities.
Cite this article:
Harshada Kailas Patil, Hetakshi Vilas Patil, Mohit Sunil Pawar, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. Safinamide Mesylate: Analytical and Chromatographic Methodologies. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):153-9. doi: 10.52711/2231-5675.2025.00024
Cite(Electronic):
Harshada Kailas Patil, Hetakshi Vilas Patil, Mohit Sunil Pawar, Sejal Tukaram Patel, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. Safinamide Mesylate: Analytical and Chromatographic Methodologies. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):153-9. doi: 10.52711/2231-5675.2025.00024 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-2-13
REFERENCES:
1. Pringsheim T, Jette N, Frolkis A. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014; 29(13): 1583–1590.
2. Fabbri, M. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener. Dis. Manag. 2015; 5: 481–496.
3. Muller, T. Emerging approaches in Parkinson’s disease — adjunctive role of safinamide. Ther. Clin. Risk Manag. 2016; 12, 1151–1160.
4. Van Dorsser W, Barris D, Cordi A. Anticonvulsant activity of milacemide. Arch Int Pharmacodyn Ther. 1983; 266:239-49.
5. Colombo M, Strolin Benedetti M. MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice. J Neural Transm Suppl. 1990; 32:123-9.
6. Pevarello P, Bonsignori A, Dostert P. Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl) amino]alkanamide derivatives. J Med Chem. 1998; 41:579-90.
7. Redasani, VK, Mali, BJ, Patil, AS, and Shirkhedkar, AA. Development and validation of RP HPLC method for determination of safinamide mesylate in bulk and in tablet dosage form. Analytical Chemistry an Indian Journal. 2013; 13(4): 127-130.
8. Marzo, A., Dal Bo, L., Monti, NC, Crivelli, F., Ismaili, S., Caccia, C., & Fariello, RG. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacological Research. 2004; 50(1): 77-85.
2. Deeks, ED. Safinamide: First Global Approval. Drugs. 2015; 75(6): 705-711.
3. Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson’s disease. Expert Opin Drug Saf. 2011; 10(4): 633–643.
4. El-Kosasy, A. M., Hussein, L. A., Mohamed, N. M., & Salama, N. N. New and validated RP HPLC Method for Quantification of Safinamide Mesylate in Presence of Its Basic Degradate, Levodopa and Ondansetron: Application to Human Plasma. Journal of Chromatographic Science. 2020; 58(9): 789-795.
5. Fariello RG. Preclinical evaluation of PNU-151774E as a novel anticonvulsant. J Pharmacol Exp Ther. 1998; 285: 397 -403.
6. Bette S, Shpiner DS, Singer C, Moore H. Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence, therapeutics and clinical. Risk Manage. 2018; 14: 1737–45.
7. Fariello RG. Safi namide. Neurotherapeutics. 2007; 4: 110 -6.
8. Fabbri, M. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener. Dis. Manag. 2015; 5: 481–496.
9. Schnitker, J. and Mu ¨ller, T. Meta-analysis of placebo-controlled clinical trials of safinamide and entacapone as add-on therapy to levodopa in the treatment of Parkinson’s disease. Eur. Neurol. Rev. 2015; 10: 15–22.
10. Muller, T. and Foley, P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin. Pharmacokinet. 2017; 56: 251–261.
11. Chazot PL. Safi namide (Newron Pharmaceuticals). Curr Opin Investing Drugs. 2001; 2: 809 -13.
12. Dal Bo L., Mazzucchelli P., Fibbioli M., and Marzo A. Bioassay of safinamide in biological fluids of humans and various animal species, Drug Research. 2006; 12: 814–819.
13. Zhang K., Xue N., Shi X., Liu W., Meng J., and Du Y. A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug. Journal of Pharmaceutical and Biomedical Analysis. 2011; 55(1): 220–224.
14. Mali Bhushan J., Vivekkumar K., Redasani K., Amod S. Patil, Atul Shirkhedkar A. Development and validation of RP-HPLC method for determination of safinamide mesylate in bulk and in tablet dosage form. Analytical Chemistry an Indian Journal. 2013; 13(4): 127-130.
15. Caccia, C. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67. 2006; (Suppl. 2): S18–S23.
16. Blair, H.A. and Dhillon, S. Safinamide: a review in Parkinson’s disease. CNS Drugs. 2017; 31: 169–176.
17. Perez-Lloret, S.; Rascol, O. The Safety and Efficacy of Safinamide Mesylate for the Treatment of Parkinson’s disease. Expert Rev. Neurother. 2016; 16: 245−258.
18. Marzo A, Dal Bo L, Monti NC. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004; 50: 77-85.
19. Leuratti C, Sardina M, Ventura P, et al. Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers. Pharmacology. 2013; 92: 207-16.
20. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs. 2008; 17: 1115-25.
21. NW1015 antiepileptic compound. Investigator’s Brochure. Newron Pharmaceuticals. October 21, 1999.
22. Caccia C, Maj R, Calabresi M. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006; 67: S18-23.
23. Binda C, Hubalek F, Li M. Structure of the human mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design. Neurology. 2006; 67(Suppl 2): S5-7.
24. Chauhan A, Mittu B, Chauhan P. Analytical method development and validation: a concise review. J Anal Bioanal Tech. 2015; 6(1): 1-5.
25. Lavanya G, Sunil M, Eswarudu MM, Eswaraiah MC, Harisudha K, Spandana BN. Analytical method validation: An updated review. Int J Pharm Sci Res. 2013; 4(4): 1280.
26. Vidushi Y, Meenakshi B. A review on HPLC method development and validation. Res J Life Sci. 2017; 2(6): 178.
27. Kumar S. Spectroscopy of organic compounds. Cosmic rays. 2006; 10: 4.
28. Chatwal GH. Textbook of quantitative Chemical Analysis. Himalaya Publishing House. 2002.
29. Chawla G, Chaudhary KK. A review of HPLC technique covering its pharmaceutical, environmental, forensic, clinical and other applications. Int J Pharm Chem Anal. 2019; 6 (2): 27-39.
30. Attimarad M, Ahmed KK, Aldhubaib BE, Harsha S. High-performance thin layer chromatography: A powerful analytical technique in pharmaceutical drug discovery. Pharm Methods. 2011 Apr; 2(2): 71-5. Doi: 10.4103/2229-4708.84436.
31. Namratha Sunkara, B. Manisha, B. Harshita, B. Anjali, B. Ishwarya, B. Akhila Gas chromatography. World Journal of Pharmaceutical Science and Research. 2024; 3(1): 23-26.
32. MacNair JE, Lewis KC, Jorgenson JW. Ultrahigh-pressure reversed-phase liquid chromatography in packed capillary columns. Anal Chem. 1997; 69(6): 983-989.
33. Walter TH, Andrews RW. Recent innovations in UHPLC columns and instrumentation. TrAC Trends Anal Chem. 2014; 63: 14-20.
34. Dusakanti Akhila, Pasupuleti Sunitha, Vijaya Kuchana. Stability indicating RP-HPLC analytical method development and validation for the estimation of safinamide in bulk and marketed pharmaceutical dosage form. International Journal of Multidisciplinary Research and Growth Evaluation. January-February 2024; 5(1): 93-99.
35. Gayatri R. Amrutkar, Smita S Aher and R S Bachhav. Stability Indicating RP-HPLC Method Development and Validation for Estimation of Safinamide in Bulk Drug and Dosage Form. International Journal of Pharmacy and Biological Sciences. Oct 2022; 12(4): 92-106.
36. Madhu Medabalimi, K. Saravanakumar and S.V. Satyanarayana. Development and Validation of Stability Indicating RP-UPLC Method for Quantitative Estimation of Safinamide Mesylate in Bulk and its Tablet Dosage Form. Current Trends in Biotechnology and Pharmacy. 2022; 16(2): 50- 59.
37. Ayesha Rehman, Pasupathi Nath Tiwari, Sreenivas Rao. Development and validation of an RP-HPLC method for the determination of safinamide mesylate in bulk and pharmaceutical dosage form. Asian Journal of Pharmaceutical Analysis. 2022; 12(3): 173- 178.
38. Ayesha Rehman, Pasupati Nath Tiwar, Harsha K. Tripathy, C. Sreedhar. Method for determination of Safinamide mesylate in bulk and tablet dosage form by both RP-HPLC and HPTLC. Journal of Emerging Technologies and Innovative Research. August 2021; 8(8).
39. V. Shirisha, Gurram Srikanth, Santhosh Illendula, K. Rajeswar Dutt. Rp-HPLC method development and validation for the Estimation of safinamide in API form and marketed Formulation. International Journal of Research. February 2021; X (II): 402-417.
40. Amira M. El-Kosasy, Lobna A. Hussein, Nesma M. Mohamed and Nahla N. Salama. New and validated RP-HPLC Method for Quantification of Safinamide Mesylate in Presence of Its Basic Degradate, Levodopa and Ondansetron: Application to Human Plasma. Journal of Chromatographic Science. 10 Aug 2020; 58(9): 789–795.
41. Vaibhav S. Adhao, Raju R. Thenge, J. Sharma, M. Thakare. Development and Validation of Stability Indicating RP-HPLC Method for Determination of Safinamide Mesylate. Jorden journal of pharmaceutical science. 2020; Volume 13, No. 2.
42. Vivekkumar K. Redasani, Bhushan J. Mali, and Sanjay J. Surana. Development and Validation of HPTLC Method for Estimation of Safinamide Mesylate in Bulk and in Tablet Dosage Form. International Scholarly Research Notices. Volume 2012: 1-4.